医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

iPug, the Innovative Digital Health Platform Founded in Australia, Announces Their US Launch at the BIO International Convention 2016

2016年06月06日 AM09:45
このエントリーをはてなブックマークに追加


 

SAN FRANCISCO

iPug is a mobile friendly platform that transforms the way that research is conducted and how public health campaigns are delivered. With iPug Research Suite™, iPug recruits and engages targeted participants for high quality and real-time research results. iPug Health Suite also delivers individualized health campaigns to individuals with the right message, at the right time, on the right device with the right reward incentive, thereby moving governments away from a broadcast model of ineffective public service campaigns to a targeted reward-based communications platform. This level of engagement has proven to save time, money and has a higher success rate in influencing changed user behavior as it relates to public health.

Speaking on the emergence of digital health technology in the US and the opportunity for iPug, Steve Huff, CEO and Co-Founder of iPug, said, “It is an exciting time to be in digital health. Digital health funding is up with over $900m in investment in Q1 of this year. This represents a 50% year on year growth from the same time last year.”

After successfully launching in Australia and most notably developing the injury prevention app Cool Runnings for the Center for Children’s Burns and Trauma Research in Brisbane, iPug sees tremendous opportunity in the US to reduce public agency costs, effectively scale and deliver measurable results for public health campaigns.

At BIO, iPug will be at the Australian Pavilion from June 6-9th.

About iPug:

iPug is the world’s first mobile friendly platform that transforms the way that public research is conducted and how public health campaigns are delivered through mobile gamification.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160605005105/en/

CONTACT

iPug
Priya Ghandikota, 1 408-887-7094
press@ipug.co

同じカテゴリーの記事 

  • joimax® Obtains Registration for All Products in the Indian Market
  • Avistone Announces the Approval of Vebreltinib as the First MET-TKI Treatment for a Rare Brain Glioma Subtype in China
  • Inocras Pioneers Precision Health with Revolutionary Whole Genome Insights
  • エクセルゲン、バクスター・インターナショナルを提訴。口腔体温計の精度に関するデータの公表権を擁護
  • パース・バイオサイエンシズが研究室用自動化プロバイダー・プログラムをローンチし、ハミルトン、オープントロンズ、ラボワークス、SPTラボテックと提携